NCT04883138 is a Phase 1 clinical trial of GIGA-2050 in COVID-19, sponsored by GigaGen, Inc..

Who is sponsoring NCT04883138?

NCT04883138 is sponsored by GigaGen, Inc..

What drugs are being tested in NCT04883138?

Interventions in NCT04883138: GIGA-2050.

Is NCT04883138 still recruiting?

NCT04883138 is currently terminated. Last updated 26 January 2022.

Last reviewed 2022-01-26 · How we verify

NCT04883138

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients

Terminated Phase 1 Last updated 26 January 2022

What this trial tests

Phase 1 trial testing GIGA-2050 in COVID-19 in 3 participants. Terminated before completion.

Timeline

24 May 2021

Primary endpoint
11 January 2022

11 January 2022

Quick facts

Lead sponsor	GigaGen, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	24 May 2021
Primary completion	11 January 2022
Estimated completion	11 January 2022
Sites	1 location across United States

Drugs / interventions tested

GIGA-2050 — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

GigaGen, Inc. — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
Strohl WR, Ku Z, An Z, Carroll SF, et al · · 2022 · cited 31× · PMID 35476216 · DOI 10.1007/s40259-022-00529-7
Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron)
Vanhove B, Marot S, Evanno G, Malet I, et al · · 2022 · DOI 10.1101/2022.01.26.477856

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04883138 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GigaGen, Inc.
Last refreshed: 26 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04883138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing